Page last updated: 2024-10-24

carvedilol and Dyslipidemias

carvedilol has been researched along with Dyslipidemias in 2 studies

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research Excerpts

Excerpt	Relevance	Reference
"We aimed to investigate the acute and chronic effects of carvedilol on insulin resistance in high-fructose, high-fat diet (HFrHFD) - fed mice and the implication of the β-arrestin2 pathway."	4.12	Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF; Mohamed, SG; Rezk, AM, 2022)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Ahmed, HMS	1
Mohamed, SG	1
Ibrahim, WS	1
Rezk, AM	1
Mahmoud, AAA	1
Mahmoud, MF	1
Ibrahim, IAAE	1
Bakris, GL	1
Tarka, EA	1
Waterhouse, B	1
Goulding, MR	1
Madan, A	1
Anderson, KM	1
St John Sutton, M	1
Miller, AB	1
Reichek, N	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Re[NCT00108082]			Phase 3	287 participants (Actual)	Interventional	2005-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12

LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	grams (g) (Mean)
Carvedilol CR	-13.74
Atenolol	-14.17
Lisinopril	-17.17

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12

LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	grams per meters squared (g/m^2) (Mean)
Carvedilol CR	-20.35
Atenolol	-20.06
Lisinopril	-18.48

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12

LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	grams per meters squared (g/m^2) (Mean)
Carvedilol CR	-6.34
Atenolol	-6.67
Lisinopril	-7.94

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12

LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)

Intervention	g/m raised to 2.7 (g/(m^2.7)) (Mean)
Carvedilol CR	-11.78
Atenolol	-12.51
Lisinopril	-11.61

Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12

LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	g/m raised to 2.7 (g/(m^2.7)) (Mean)
Carvedilol CR	-3.19
Atenolol	-3.37
Lisinopril	-3.98

Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12

LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	grams (Mean)
Carvedilol CR	-45.76
Atenolol	-40.56
Lisinopril	-38.58

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12

Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

Intervention	percentage of change (Geometric Mean)
Carvedilol CR	-27.1
Atenolol	-20.1
Lisinopril	-21.5

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12

BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) [Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value]. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used

Intervention	percentage of change (Geometric Mean)
Carvedilol CR	51.7
Atenolol	48.3
Lisinopril	-39.1

Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12

CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

Intervention	percentage of change (Geometric Mean)
Carvedilol CR	-10.63
Atenolol	-3.22
Lisinopril	2.70

Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12

LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume). (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	milliliters (mL) (Mean)
	LV E-volume	LV A-volume
Atenolol	6.763	-0.565
Carvedilol CR	0.364	-0.513
Lisinopril	-3.406	1.088

Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12

LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	milliliters (mL) (Mean)
	LV End Systolic Volume	LV End Diastolic Volume	LV Ejection Fraction
Atenolol	-4.74	-3.64	2.33
Carvedilol CR	-3.38	-3.07	1.03
Lisinopril	-5.34	-9.37	0.63

Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12

LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	milliliters (mL) (Mean)
	LV End Systolic Volume	LV End Diastolic Volume	LV Ejection Fraction
Atenolol	-4.29	-2.45	2.16
Carvedilol CR	-1.44	-2.86	0.08
Lisinopril	-3.04	-7.45	-0.01

Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12

Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)

Intervention	mmHg (millimeters of mercury) (Mean)
	Systolic blood pressure	Diastolic blood pressure
Atenolol	-21.12	-14.05
Carvedilol CR	-21.32	-12.77
Lisinopril	-22.53	-11.13

Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12

Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). [Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.] (NCT00108082)
Timeframe: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)

Intervention	percentage of change (Geometric Mean)
	Total cholesterol	Low-density lipid cholesterol	High-density lipid cholesterol	Triglycerides
Atenolol	-1.3	-4.0	-4.7	7.1
Carvedilol CR	0.7	0.0	-4.3	11.0
Lisinopril	-1.7	-2.7	-1.5	6.2

Other Studies

2 other studies available for carvedilol and Dyslipidemias

Article	Year
Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway. Canadian journal of physiology and pharmacology, 2022, Volume: 100, Issue:1 Topics: Animals; beta-Arrestin 2; Carvedilol; Diet, High-Fat; Dietary Carbohydrates; Diglycerides; Dyslipide	2022
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. The American journal of cardiology, 2006, Oct-02, Volume: 98, Issue:7A Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Delayed-Action Prepara	2006